Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Roger Stupp MD

Roger Stupp MD

Paul C. Bucy Professor of Neurological Surgery; Professor of Medicine (Hematology/Oncology) and Neurology, Northwestern University Feinberg School of Medicine; Co-Director, Northwestern Medicine Malnati Brain Tumor Institute; Associate Director for Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

Dr. Roger Stupp is an internationally recognized neuro-oncologist and a leading authority on primary and metastatic brain cancer. He serves as Professor and Medical Director of the Malnati Brain Tumor Institute in the Department of Neurological Surgery and Division Chief of Neuro-Oncology in the Department of Neurology as well as Associate Director for Strategic Initiatives at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago.

Dr. Stupp is an active and dedicated clinical researcher. His special clinical interests include the multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers, as well as new drug development and the association of chemotherapy and radiation therapy. He is also closely involved in bringing new antiangiogenic and biological treatments to the clinic. He is part of Northwestern University’s Brain Tumor SPORE leadership, and he maintains close collaborations with its basic and translational research laboratories.

After receiving his medical degree from the University of Zürich Medical School and undergoing residencies in internal medicine and clinical immunology, Dr. Stupp completed fellowship training in medicine and hematology/oncology at the University of Chicago Hospitals and Cancer Center, Chicago, Illinois.

Disclosures

  • Advisory boards: Celularity; GT Medical Technologies; DNAtrix; Northwest Biotherapeutics; several non–clinical stage biotech companies

Recent Contributions to PracticeUpdate:

  1. Bevacizumab for Newly Diagnosed Glioblastoma: More Disappointment
  2. No Go With Bevacizumab in Newly Diagnosed Glioblastoma
  3. No Overall Survival Benefit With Addition of Bevacizumab to Radiotherapy/Temozolomide in Glioblastoma
  4. Frequently Asked Questions in Oncology: Neuro-Oncology
  5. Glioblastoma: Despite All the Disappointment, There Has Been Progress
  6. Low-Grade Glioma
  7. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
  8. Roger Stupp Receives 2013 Hamilton Fairley Award
  9. Dr. Roger Stupp's ASCO Abstract Recommendations—Neuro-Oncology
  10. Top Stories of 2012: Making Strides Toward Molecular Profiling in Central Nervous System Cancers

Most Read This Week

Recently Updated